ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > not too shabby

<< Previous

Bullboard Posts

Next >>

Comment by farmerjaneon Oct 22, 2021 11:49am

136 Views

Post# 34037686

RE:not too shabby

Just trying to provide a deflection from yesterdays announcent. They have added Gavin Mallenfant chief operating officer, Dennis Chin Head of Manufacturing, Michael Grundman Senior Medical Advisor. Board of Directors have six listed but actually have eight.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features